Faruqi & Faruqi Investigates Rocket Pharmaceuticals Securities Litigation

Faruqi & Faruqi LLP is investigating potential claims against Rocket Pharmaceuticals due to alleged securities violations. Investors who purchased securities between February 27, 2025 and May 26, 2025 are encouraged to contact Josh Wilson directly at 877-247-4292 or 212-983-9330. The deadline to seek the role of lead plaintiff is August 11, 2025.

Investors who purchased or acquired Rocket Pharmaceuticals, Inc. (RCKT) securities between February 27, 2025, and May 26, 2025, are encouraged to contact the law offices of Faruqi & Faruqi, LLP, to discuss their legal options. The firm has set August 11, 2025, as the deadline for investors to seek the role of lead plaintiff in a federal securities class action lawsuit against the company [2].

The lawsuit alleges that Rocket Pharmaceuticals made materially false and misleading statements and failed to disclose critical information about its clinical trial, RP-A501, for the treatment of Danon disease. Specifically, the complaint claims that Rocket knew of Serious Adverse Events (SAEs), including the death of participants, but did not disclose these risks to investors [2]. Additionally, the company amended the trial's protocol to introduce a novel immunomodulatory agent without informing shareholders [2].

On May 27, 2025, Rocket announced that the FDA had placed a clinical hold on the RP-A501 Phase 2 pivotal study following an SAE, which led to a significant drop in the company's stock price. Rocket's stock price fell from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, a decline of about 37% [2].

Investors who believe they have been affected by these alleged securities violations are urged to contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights [2].

References:
[1] https://www.morningstar.com/news/business-wire/20250808067854/deadline-soon-rocket-pharmaceuticals-inc-rckt-investors-who-lost-money-urged-to-contact-the-law-offices-of-frank-r-cruz-about-securities-fraud-lawsuit
[2] https://www.prnewswire.com/news-releases/faruqi--faruqi-reminds-rocket-pharmaceuticals-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-august-11-2025---rckt-302525501.html
[3] https://www.marketscreener.com/news/faruqi-faruqi-reminds-rocket-pharmaceuticals-investors-of-the-pending-class-action-lawsuit-with-a-ce7c5ed2d981f121